| Citation: |
ZHANG Linyuan, ZHANG Jinbo, TAO Yongming, CHANG Yanjun, LIU Weikai. Effects of growth hormone on in vitro fertilization-embryo transfer in patients with polycystic ovary syndrome[J]. Journal of Clinical Medicine in Practice, 2023, 27(4): 48-51. DOI: 10.7619/jcmp.20222139
|
To investigate the effect of growth hormone (GH) on in vitro fertilization-embryo transfer (IVF-ET) in patients with polycystic ovary syndrome (PCOS).
A total of 110 PCOS patients were selected and divided into GH group and control group by random number table method, with 55 cases in each group. Both groups were treated with IVF-ET, and the GH group innovatively received intramuscular injection of recombinant human growth hormone(rhGH) during ovulation induction. The serum GH and insulin-like growth factor-1 (IGF-1) levels before treatment and on the injection day of human chorionic gonadotropin (HCG), levels of GH and IGF-1 in follicular fluid on the day of egg retrieval, development of oocytes, and IVF-ET outcomes of the two groups were compared.
On HCG day, the serum GH, IGF-1 in the GH group were significantly increased than before treatment (P < 0.05), while the control group had no significant change compared with the treatment before (P>0.05). The serum GH, and serum IGF-1 on HCG day in the GH group were (9.76±2.32) μg/L and (146.54±23.79) μg/L, which were higher than (2.04±0.53) μg/L and (109.88±21.05) μg/L in the control group(P < 0.05); the follicular fluid GH and IGF-1 on the day of oocyte retrieval in the GH group were (3.18±0.52) μg/L and (101.42±17.36) μg/L, which were higher than (2.66±0.48) μg/L and (89.17±13.58) μg/L in control group, the differences were statistically significant (P < 0.05). There were no significant difference in the number of ovum in GV stage and MⅠstage between the two groups (P>0.05). The number ovum in M Ⅱ stage in the GH group was (15.16±3.23), which was higher than (10.78±2.59) in control group (P < 0.05). The fertilization rate, cleavage rate and high quality embryo rate of the GH group were 86.93%, 93.66% and 49.66%, which were higher than 80.61%, 88.91% and 41.84% in control group (P < 0.05).
The exogenous supplementation of GH in the process of ovulation induction in PCOS patients can increase the content of GH and IGF-1 in serum and follicular fluid, synergistically promote oocyte development and oocyte development, and increase ICSI fertilization rate and high-quality embryo rate.
| [1] |
李扬璐, 阮祥燕. 多囊卵巢综合征与不良妊娠结局的研究进展[J]. 中国临床医生杂志, 2021, 49(1): 8-11. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS202101003.htm
|
| [2] |
董亚光, 朱琳, 陈浩暘. 多囊卵巢综合征产科并发症及其机制的研究进展[J]. 实用临床医药杂志, 2022, 26(9): 112-116. doi: 10.7619/jcmp.20214639
|
| [3] |
秦爽, 阮祥燕, 王宾红, 等. 多囊卵巢综合征患者促排卵周期中成熟卵泡性激素浓度对妊娠的影响[J]. 首都医科大学学报, 2020, 41(4): 530-535. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYD202004007.htm
|
| [4] |
中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ201810010.htm
|
| [5] |
田莉, 王婷, 卢娜, 等. 生长激素不同应用时间对IVF助孕结局的影响[J]. 生殖医学杂志, 2020, 29(2): 188-192. https://www.cnki.com.cn/Article/CJFDTOTAL-SZYX202002011.htm
|
| [6] |
肖亚玲, 孙正怡. 胚胎形态学评估的临床应用价值[J]. 中华生殖与避孕杂志, 2020, 40(1): 60-64.
|
| [7] |
邬晓琳, 黄玲玲, 梁蕾, 等. 重组人生长激素在人类辅助生殖技术助孕中的应用进展[J]. 中华生殖与避孕杂志, 2020, 40(3): 241-245.
|
| [8] |
吴正中, 李雪梅, 刘兰云, 等. 生长激素改善多囊卵巢综合症患者卵母细胞成熟度的研究[J]. 生殖医学杂志, 2019, 28(11): 1346-1351. https://www.cnki.com.cn/Article/CJFDTOTAL-SZYX201911019.htm
|
| [9] |
ESMAEILINEZHAD Z, BABAJAFARI S, SOHRABI Z, et al. Effect of synbiotic pomegranate juice on glycemic, sex hormone profile and anthropometric indices in PCOS: a randomized, triple blind, controlled trial[J]. Nutr Metab Cardiovasc Dis, 2019, 29(2): 201-208.
|
| [10] |
江波. 代谢相关性多囊卵巢综合征及其理论基础[J]. 实用临床医药杂志, 2021, 25(2): 1-4, 9. doi: 10.7619/jcmp.20210388
|
| [11] |
ZEHRAVI M, MAQBOOL M, ARA I. Polycystic ovary syndrome and infertility: an update[J]. Int J Adolesc Med Health, 2021, 34(2): 1-9.
|
| [12] |
MELDRUM D R, QUAAS A M, SU H I. Why is growth hormone underutilized for our most difficult IVF couples?[J]. Fertil Steril, 2018, 110(7): 1261-1262.
|
| [13] |
NORMAN R J, ALVINO H, HULL L M, et al. Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate[J]. Reprod Biomed Online, 2019, 38(6): 1261-1262.
|
| [14] |
黄惠娟, 向伟楚, 王晶, 等. 多囊卵巢综合征患者GH、IGF-1水平检测对预测体外受精-胚胎移植结局的价值[J]. 中国优生与遗传杂志, 2019, 27(3): 368-370, 286. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYA201903042.htm
|
| [15] |
LAZUROVA I, FIGUROVA J, LAZUROVA Z, et al. Insulin-like growth factor (IGF) system and hormonal-metabolic profile in women with polycystic ovary syndrome[J]. Bratisl Lek Listy, 2021, 122(7): 469-473.
|
| [16] |
TULAY P, ONAL T, VATANSEVER S. Molecular regulation of polycystic ovary syndrome: altered gene expression levels in mouse models pretreatment and post-treatment[J]. Zygote, 2022, 30(3): 352-357.
|
| [17] |
TAHERI M, HAYATI ROUDBARI N, AMIDI F, et al. The protective effect of sulforaphane against oxidative stress in granulosa cells of patients with polycystic ovary syndrome (PCOS) through activation of AMPK/AKT/NRF2 signaling pathway[J]. Reprod Biol, 2021, 21(4): 100563-100566.
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: